Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Hematology | Cardiology/Vascular Diseases | Family Medicine
Stroke Clinical Trials
A listing of Stroke medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Alexander City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Athens : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Birmingham : University of Alabama
A Study of Modified Stem Cells in Stable Ischemic Stroke
Birmingham : The University of Alabama at Birmingham
Aspirin in Reducing Events in the Elderly
Birmingham : 1160.129.32261 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Birmingham : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Birmingham : University of Alabama
Safety of Intravenous Thrombolysis for Wake-up Stroke
Gulf Shores : 1160.129.32023 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Huntsville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Mobile : University of South Alabama
Insulin Resistance Intervention After Stroke Trial
Mobile : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pell City : 1160.129.32172 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Scottsboro : 1160.129.32054 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sheffield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tuscaloosa : 1160.129.32174 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Alaska
Arizona
Chandler : 1160.129.32254 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Gilbert : Mercy Gilbert and Chandler Medical Center
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
Glendale : 1160.129.32284 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Glendale : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hot Springs : 1160.129.32156 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Lake Havasu City : 1160.129.32151 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Phoenix : 1160.129.32250 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Phoenix : 1160.129.32159 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Phoenix : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Phoenix : Carl T. Hayden Medical Research Foundation
SmartRisk Stroke Prediction by MRI of Carotid Disease
Tucson : University of Arizona
Insulin Resistance Intervention After Stroke Trial
Arkansas
Fort Smith : 1160.129.32266 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hot Springs : 1160.129.32140 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jonesboro : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Little Rock : 1160.129.32009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Little Rock : 1160.129.32014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Little Rock : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
California
Colton : SHANTI Clinical Trials
Stroke
Duarte : City of Hope Updated
Modifiable Risk Factors in Stroke Incidence and Mortality Among Women
View More »
Alhambra : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Aliso Viejo : Avanir Pharmaceuticals
PRISM Registry: Pseudobulbar Affect Registry Series
Anaheim : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bakersfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Downey : Merz Investigational Site #001184
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Encinitas : 1160.129.32035 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fountain Valley : 1160.129.32126 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fountain Valley : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fresno : 1160.129.32019 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fresno : UCSF-Fresno
Insulin Resistance Intervention After Stroke Trial
Garden Grove : Merz Investigational Site #001208
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Hawaiian Gardens : 1160.129.32305 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hollywood : 1160.129.32230 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
La Jolla : 1160.129.32225 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
La Jolla : Scripps Clinic
Insulin Resistance Intervention After Stroke Trial
La Mesa : 1160.129.32216 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
La Mesa : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Larkspur : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lomita : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Los Alamitos : 1160.129.32039 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Los Angeles : UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center)
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Los Angeles : University of Southern California
Insulin Resistance Intervention After Stroke Trial
Los Angeles : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Los Angeles : Cedars-Sinai Medical Center
SmartRisk Stroke Prediction by MRI of Carotid Disease
Merced : 1160.129.32043 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Modesto : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Newport Beach : Hoag Hospital
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Newport Beach : Hoag Memorial Hospital Presbyterian
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Newport Beach : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oakland : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oceanside : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Palo Alto : Palo Alto Medical Foundation Research Institute
Aspirin in Reducing Events in the Elderly
Palo Alto : Stanford University
Insulin Resistance Intervention After Stroke Trial
Pasadena : US050
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Pasadena : Huntington Memorial Hospital Stroke Center
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Rancho Mirage : 1160.129.32170 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sacramento : University of California-Davis
Insulin Resistance Intervention After Stroke Trial
San Diego : University of California San Diego Division of Neurological Surgery
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
San Diego : 1160.129.32017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
San Diego : University of California
Insulin Resistance Intervention After Stroke Trial
San Diego : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
San Francisco : Brain Plasticity Institute Updated
Computerized Attention Training for Individuals With Acquired Brain Injury
San Francisco : California Pacific Medical Center Research Institute
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
San Francisco : University of California
Insulin Resistance Intervention After Stroke Trial
San Francisco : University of California San Francisco Stroke Sciences Group
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
San Francisco : University of California San Francisco
SmartRisk Stroke Prediction by MRI of Carotid Disease
San Marino : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Santa Ana : 1160.129.32051 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Santa Clara : Abbott Vascular
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
Santa Rosa : 1160.129.32330 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Santa Rosa : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Stanford : Stanford University School of Medicine
A Study of Modified Stem Cells in Stable Ischemic Stroke
Stockton : 1160.129.32102 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Temecula : 1160.129.32167 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ventura : 1160.129.32249 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ventura : 1160.129.32196 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ventura : 1160.129.32205 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ventura : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Visalia : 1160.129.32104 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Westlake Village : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Colorado
Aurora : 1160.129.32031 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Aurora : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Colorado Springs : 1160.129.32021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Colorado Springs : 1160.129.32204 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Colorado Springs : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
View More »
Denver : Swedish Medical Center
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Denver : Endovascular Surgical Neuroradiology, Swedish Medical Center
Assess the Penumbra System in the Treatment of Acute Stroke
Denver : Denver Health and Hospital Authority
Insulin Resistance Intervention After Stroke Trial
Englewood : Swedish Medical Center
Safety of Intravenous Thrombolysis for Wake-up Stroke
Littleton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Loveland : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Connecticut
Stamford : Stamford Therapeutics Consortium
Are You at Risk for a Heart Attack or Stroke?
Waterbury : Chase Medical Research, LLC
A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long Term Outcomes)
Waterbury : Chase Medical Research, LLC
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
View More »
Bridgeport : 1160.129.32193 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bridgeport : 1160.129.32233 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bridgeport : 1160.129.32268 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fairfield : Updated
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Fairfield : Updated
BOTOX® Treatment in Pediatric Upper Limb Spasticity
Fairfield : Merz Investigational Site #001244
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Hartford : Hartford Hospital
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Hartford : Hartford
Insulin Resistance Intervention After Stroke Trial
Hartford : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Milford : 1160.129.32008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
New Haven : Yale University School of Medicine
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
New Haven : Yale University
Insulin Resistance Intervention After Stroke Trial
Norwalk : 1160.129.32303 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Norwalk : 1160.129.32074 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Shelton : 1160.129.32152 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Stamford : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Delaware
Newark : 1160.129.32066 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Newark : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
District of Columbia
Washington : Howard University
Aspirin in Reducing Events in the Elderly
Washington : 1160.129.32202 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Washington : 1160.129.32314 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Washington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Florida
Miami : Pharmax Research Clinic, Inc.
Do you suffer from Gout and heart problems or diabetes?
St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL
Gout and a History of Cardiac Disease ITN# 09338
View More »
Aventura : 1160.129.32270 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Boca Raton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Brandon : 1160.129.32144 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Brandon : 1160.129.32292 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Clearwater : 1160.129.32119 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Clearwater : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Coral Gables : 1160.129.32304 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Coral Springs : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Crystal River : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Davie : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Daytona Beach : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Deerfield Beach : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Delray Beach : 1160.129.32048 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Doral : 1160.129.32291 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fort Lauderdale : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fort Lauderdale : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Gainesville : University of Florida Department of Aging and Geriatrics
Aspirin in Reducing Events in the Elderly
Gainesville : 1160.129.32132 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Gainesville : University of Florida
Insulin Resistance Intervention After Stroke Trial
Gainesville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hialeah : 1160.129.32310 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hialeah : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hollywood : 1160.129.32318 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hollywood : 1160.129.32128 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hollywood : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Jacksonville : University of Florida
Insulin Resistance Intervention After Stroke Trial
Jacksonville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Jupiter : 1160.129.32090 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jupiter : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lakeland : 1160.129.32079 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Largo : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Leesburg : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Melbourne : MIMA Century Research Associates
Insulin Resistance Intervention After Stroke Trial
Miami : 1160.129.32212 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32296 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32222 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32094 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32276 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32124 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : 1160.129.32076 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miami : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Miami : University of Miami
SmartRisk Stroke Prediction by MRI of Carotid Disease
Miami : University of Miami Hospital
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Miami Beach : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Miramar Beach : 1160.129.32125 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Naples : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Smyrna Beach : 1160.129.32005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oakland Park : 1160.129.32147 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ocala : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Orlando : 1160.129.32182 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Orlando : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Orlando : Rehabilitation Medical Group - Florida Hospital
SISTERS: Spasticity In Stroke Study - Randomized Study
Panama City : 1160.129.32281 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Panama City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pembroke Pines : 1160.129.32063 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Pensacola : 1160.129.32239 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Pensacola : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pensacola :
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Pismo Beach : 1160.129.32136 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Port Charlotte : 1160.129.32208 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Port Charlotte : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Rockledge : 1160.129.32259 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Safety Harbor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sarasota : Sarasota Memorial Hospital
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Sarasota : 1160.129.32313 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sarasota : 1160.129.32248 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sarasota : 1160.129.32006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sarasota : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Seminole : 1160.129.32020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
South Miami : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St. Petersburg : 1160.129.32116 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Petersburg : 1160.129.32213 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Petersburg : 1160.129.32057 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Petersburg : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tallahassee : 1160.129.32064 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Tallahassee : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tampa : 1160.129.32277 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Tampa : Floria Neurovascular Institute
Insulin Resistance Intervention After Stroke Trial
The Villages : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Wellington : 1160.129.32037 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Wellington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
West Palm Beach : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Georgia
Atlanta : Grady Health System
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Atlanta : Emory University
A Study of Modified Stem Cells in Stable Ischemic Stroke
Atlanta : Morehouse School of Medicine
Aspirin in Reducing Events in the Elderly
Atlanta : Emory/ Atlanta VAMC
Aspirin in Reducing Events in the Elderly
Atlanta : US109
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
View More »
Atlanta : Emory University
Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients
Atlanta : 1160.129.32253 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Atlanta : 1160.129.32302 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Atlanta : 1160.129.32178 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Atlanta : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Atlanta : Emory University School of Medicine
Rehabilitation of the Stroke Hand at Home
Augusta : US042
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Augusta : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Augusta : Georgia Health Sciences University
Study to Examine the Effects of MultiStem in Ischemic Stroke
Cumming : 1160.129.32185 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Cumming : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Decatur : 1160.129.32083 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hawaii
Honolulu : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Idaho
Boise : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Boise : Saint Alphonsus Regional Med Center
SISTERS: Spasticity In Stroke Study - Randomized Study
Coeur d'Alene : 1160.129.32096 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Illinois
Arlington Heights : 1160.129.32283 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bannockburn : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Belleville : 1160.129.32071 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : Northwestern University Feinberg School of Medicine
A Study of Modified Stem Cells in Stable Ischemic Stroke
Chicago : Rush Alzheimer's Disease Center
Aspirin in Reducing Events in the Elderly
View More »
Chicago : 1160.129.32298 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : 1160.129.32103 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : 1160.129.32293 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : 1160.129.32065 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : 1160.129.32044 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicago : Cook County (Stroger) Hospital
Insulin Resistance Intervention After Stroke Trial
Chicago : University of Illinois
Insulin Resistance Intervention After Stroke Trial
Chicago : Rush University
Insulin Resistance Intervention After Stroke Trial
Chicago : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Chicago : The Rehabilitation Institute of Chicago
Repetitive Transcranial Magnetic Stimulation (rTMS) to Contralesional Hemisphere in Patients With Stroke for Upper Limb Recovery
Chicago : Northwestern University
SmartRisk Stroke Prediction by MRI of Carotid Disease
Evanston : US074
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Harvey : Ingalls Memorial Hospital (NINDS-CRC site)
Insulin Resistance Intervention After Stroke Trial
Hinsdale : 1160.129.32117 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Maywood : Loyola University Medical Center
Insulin Resistance Intervention After Stroke Trial
Melrose Park : 1160.129.32003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Melrose Park : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Morton : 1160.129.32133 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Normal : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Peoria : OSF St. Francis Medical Center
Insulin Resistance Intervention After Stroke Trial
Peoria : OSF Stroke Center
IV Double and Triple Concentrated Nicardipine for Stroke and ICH
Rock Island : 1160.129.32275 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Rock Island : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Indiana
Avon : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bloomington : 1160.129.32106 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Brownsburg : 1160.129.32001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Elkhart : Indiana Medical Research
Insulin Resistance Intervention After Stroke Trial
Elkhart : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
View More »
Fort Wayne : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fort Wayne : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Franklin : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hammond : 1160.129.32046 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hammond : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Indianapolis : US016
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Indianapolis : Clarian Health / Methodist Hospital
Exclusion of the Left Atrial Appendage (LAA) With the LAAx, Inc. TigerPaw System
Indianapolis : 1160.129.32245 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Indianapolis : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
La Porte : 1160.129.32320 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Muncie : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Newburgh : 1160.129.32210 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
South Bend : 1160.129.32327 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Valparaiso : Associates In Neurology (NINDS-CRC site)
Insulin Resistance Intervention After Stroke Trial
Iowa
Ames : 1160.129.32042 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Des Moines : US072
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Des Moines : Ruan Neuroscience Center/Mercy Medical Center
Insulin Resistance Intervention After Stroke Trial
Des Moines : Iowa Health Des Moines Clinical Trials Office
Insulin Resistance Intervention After Stroke Trial
Iowa City : University of Iowa
Aspirin in Reducing Events in the Elderly
View More »
Iowa City : University of Iowa
Insulin Resistance Intervention After Stroke Trial
Iowa City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Waterloo : 1160.129.32055 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Waterloo : Northeast Iowa Medical Education Foundation (NINDS-CRC site)
Insulin Resistance Intervention After Stroke Trial
West Des Moines : 1160.129.32089 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kansas
Wichita : Via Christi Research
THERAPY: Assess the Penumbra System to Treat Acute Stroke
View More »
Hutchinson : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Kansas City : Kansas University Medical Center
Aspirin in Reducing Events in the Elderly
Overland Park : Merz Investigational Site # 001110
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Overland Park : 1160.129.32029 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Wichita : Via Christi Regional Medical Center
Insulin Resistance Intervention After Stroke Trial
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Rehabilitation: Have You or Someone You Know Experienced a Stroke?
Lexington : University of Kentucky Chandler Medical Center
Stroke: Research Study Have You or Someone You Know Experienced a Stroke?
View More »
Bowling Green : 1160.129.32010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Crestview Hills : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Elizabethtown : 1160.129.32025 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lexington : University of Kentucky Research Foundation
Insulin Resistance Intervention After Stroke Trial
Lexington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Louisville : University of Louisville
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Louisville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Mount Sterling : 1160.129.32188 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Owensboro : 1160.129.32059 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Louisiana
Alexandria : 1160.129.32176 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Alexandria : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Baton Rouge : Pennington Biomedical Research Center
Aspirin in Reducing Events in the Elderly
Baton Rouge : 1160.129.32286 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bossier City : 1160.129.32201 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Covington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hammond : 1160.129.32045 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kenner : 1160.129.32271 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lafayette : 1160.129.32056 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lake Charles : 1160.129.32169 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lake Charles : 1160.129.32214 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lake Charles : 1160.129.32235 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Minden : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Iberia : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Orleans : 1160.129.32274 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Opelousas : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Shreveport : Louisiana State University Health Sciences Center
Insulin Resistance Intervention After Stroke Trial
Shreveport : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Slidell : 1160.129.32164 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Slidell : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Maine
Auburn : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bangor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Biddeford : 1160.129.32122 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Biddeford : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Portland : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
View More »
Rockport : Penobscot Bay Neurology
Insulin Resistance Intervention After Stroke Trial
Maryland
Baltimore : Spectrum Clinical Research, Inc.
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)
Baltimore : Spectrum Clinical Research, Inc.
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)
View More »
Annapolis : 1160.129.32226 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Baltimore : US014
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Baltimore : 1160.129.32228 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Baltimore : 1160.129.32207 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Baltimore : Johns Hopkins
Insulin Resistance Intervention After Stroke Trial
Baltimore : Sinai Hospital of Baltimore
Insulin Resistance Intervention After Stroke Trial
Baltimore : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Baltimore : The Johns Hopkins Hospital
Safety of Intravenous Thrombolytics in Stroke on Awakening
Baltimore : Johns Hopkins Bayview Medical Center
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
Baltimore : Johns Hopkins Hospital
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
Columbia : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Columbia : Howard County General Hospital
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
Glen Burnie : 1160.129.32247 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oxon Hill : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Salisbury : 1160.129.32148 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Salisbury : 1160.129.32155 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Salisbury : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St. Louis : Merz Investigational Site #001210
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Takoma Park : 1160.129.32256 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Towson : 1160.129.32229 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Massachusetts
Ayer : 1160.129.32203 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ayer : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Boston : US039
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Boston : US003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Boston : Massachusetts General Hospital
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
View More »
Boston : Beth Israel Deaconess
Insulin Resistance Intervention After Stroke Trial
Boston : Boston University
Insulin Resistance Intervention After Stroke Trial
Boston : Massachusetts General Hospital
Insulin Resistance Intervention After Stroke Trial
Boston : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Boston : Tufts Medical Center
SmartRisk Stroke Prediction by MRI of Carotid Disease
Boston : Beth Israel Deaconess Medical Center
SmartRisk Stroke Prediction by MRI of Carotid Disease
Boston : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Charlestown : Myomo Inc
Myomo e100 NeuroRobotic System Home Safety Study
Fall River : 1160.129.32013 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Haverhill : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Natick : 1160.129.32294 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Newton : 1160.129.32289 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
North Dartmouth : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Michigan
Alpena : 1160.129.32036 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Alpena : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Ann Arbor : University of Michigan
Aspirin in Reducing Events in the Elderly
Ann Arbor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bay City : 1160.129.32234 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Detroit : Wayne State University
Aspirin in Reducing Events in the Elderly
Detroit : 1160.129.32135 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Detroit : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Detroit : Wayne State University
SmartRisk Stroke Prediction by MRI of Carotid Disease
Detroit : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
East Lansing : Michigan State University
SmartRisk Stroke Prediction by MRI of Carotid Disease
Flint : 1160.129.32047 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Flint : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Grand Blanc : 1160.129.32168 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Grand Blanc : 1160.129.32264 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Grand Blanc : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Grand Rapids : Spectrum Health
AMPLATZER Cardiac Plug Clinical Trial
Grand Rapids : US078
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Grand Rapids : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Jackson : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lansing : 1160.129.32052 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lapeer : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Marquette : 1160.129.32142 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Marquette : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Mount Clemens : 1160.129.32232 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Niles : 1160.129.32053 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Novi : Detroit Clinical Research Center
Aspirin in Reducing Events in the Elderly
Novi : 1160.129.32282 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Petoskey : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pontiac : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Rochester : 1160.129.32134 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Royal Oak : US113
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Saginaw : 1160.129.32075 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saginaw : 1160.129.32231 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saginaw : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Southfield : Providence Hospital
AMPLATZER Cardiac Plug Clinical Trial
Southfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Ypsilanti : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Minnesota
Baxter : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Chaska : 1160.129.32024 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Duluth : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Golden Valley : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Minneapolis : Health Partners Research Foundation
Aspirin in Reducing Events in the Elderly
View More »
Minneapolis : 1160.129.32280 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Minneapolis : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Minneapolis : Minneapolis Heart Institute
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Robbinsdale : Minneapolis Clinic of Neurology
Insulin Resistance Intervention After Stroke Trial
Robbinsdale : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Robbinsdale : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
St. Cloud : 1160.129.32190 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Cloud : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St. Paul : St. Joseph Hospital- Healtheast
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
St. Paul : HealthEast St. Joseph's Hospital
AMPLATZER Cardiac Plug Clinical Trial
St. Paul : Phalen Village Clinic
Aspirin in Reducing Events in the Elderly
St. Paul : 1160.129.32307 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mississippi
Biloxi : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tupelo : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Missouri
Columbia : Merz Investigational Site #001209
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Kansas City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St. Louis : 1160.129.32101 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Louis : 1160.129.32297 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Louis : 1160.129.32184 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
St. Louis : 1160.129.32143 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Louis : Washington University
Insulin Resistance Intervention After Stroke Trial
St. Louis : St. Louis University
Insulin Resistance Intervention After Stroke Trial
St. Louis : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Montana
Billings : Billings Clinic
Insulin Resistance Intervention After Stroke Trial
Billings : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Great Falls : Advanced Neurology Specialists
Insulin Resistance Intervention After Stroke Trial
Great Falls : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Kalispell : 1160.129.32165 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Kalispell : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Nebraska
Lincoln : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Omaha : 1160.129.32321 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Omaha : University of Nebraska
Insulin Resistance Intervention After Stroke Trial
Omaha : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Papillion : 1160.129.32199 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Papillion : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Nevada
Reno : 1160.129.32180 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Reno : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Hampshire
Lebanon : US077
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Lebanon : Dartmouth Hitchcock Medical Center
Insulin Resistance Intervention After Stroke Trial
New Jersey
Bridgewater : 1160.129.32154 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bridgewater : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Camden : Cooper University Hospital
Insulin Resistance Intervention After Stroke Trial
Edison : US055
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Elizabeth : Central Jersey Medical Center
Aspirin in Reducing Events in the Elderly
View More »
Elizabeth : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Elmer : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Englewood : 1160.129.32181 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Haddon Heights : 1160.129.32179 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Haddon Heights : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hammonton : 1160.129.32198 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Linden : 1160.129.32030 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Linden : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Neptune : 1160.129.32049 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ocean : 1160.129.32242 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Paterson : 1160.129.32255 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ridgewood : US100
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Ridgewood : 1160.129.32221 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ridgewood : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Saddle Brook : Kessler Institute for Rehabilitation
Study of Robot-assisted Arm Therapy for Acute Stroke Patients
Somerset : 1160.129.32099 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Somerset : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
South Plainfield : 1160.129.32007 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Stratford : Merz Investigational Site #001198
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Voorhees : 1160.129.32069 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
West Orange : 1160.129.32269 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
West Orange : Kessler Medical Rehab Research Corp
Insulin Resistance Intervention After Stroke Trial
New Mexico
Albuquerque : University of New Mexico
Insulin Resistance Intervention After Stroke Trial
Albuquerque : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New York
New Hyde Park : Biomedical Research Alliance of New York
Stroke- Micardis
View More »
Albany : US075
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Albany : 1160.129.32332 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Albany : Albany Medical Center
Insulin Resistance Intervention After Stroke Trial
Bronx : 1160.129.32173 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Bronx : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bronxville : 1160.129.32084 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Brooklyn : 1160.129.32246 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Brooklyn : SUNY Downstate
Insulin Resistance Intervention After Stroke Trial
Brooklyn : New York Methodist Hospital
Insulin Resistance Intervention After Stroke Trial
Buffalo : Kaleida Health
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Buffalo : US012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Buffalo : SUNY Buffalo
Insulin Resistance Intervention After Stroke Trial
Buffalo : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Buffalo : Kaleida Health/Buffalo General
Solitaire™ FR as Primary Treatment for Acute Ischemic Stroke
Buffalo : Millard Fillmore Gates Circle Hospital
Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention
Cortlandt Manor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Huntington : 1160.129.32195 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Johnson City : 1160.129.32278 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mineola : Winthrop University Hospital
Aspirin in Reducing Events in the Elderly
Mineola : 1160.129.32038 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mineola : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Windsor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New York : Columbia University Medical Center
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
New York : 1160.129.32110 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
New York : Gotham Cardiovascular Research PC
SmartRisk Stroke Prediction by MRI of Carotid Disease
New York : New York University School of Medicine
SmartRisk Stroke Prediction by MRI of Carotid Disease
New York : New York University School of Medicine
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
Plainview : Merz Investigational Site #001207
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Poughkeepsie : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Rochester : University of Rochester
Insulin Resistance Intervention After Stroke Trial
Saratoga Springs : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Southampton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Stony Brook : Stony Brook University Hospital
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Stony Brook : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Syracuse : 1160.129.32139 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Syracuse : 1160.129.32015 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Syracuse : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
West Seneca : Southtowns Neurology of WNY (NINDS-CRC site)
Insulin Resistance Intervention After Stroke Trial
Westfield : 1160.129.32263 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
White Plains : Burke Medical Research Institute
Insulin Resistance Intervention After Stroke Trial
Williamsville : 1160.129.32209 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Williamsville : 1160.129.32016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Williamsville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
North Carolina
Greensboro : Guilford Neurologic Associates
Do you have foot drop as a result of a stroke?
Greensboro : Guilford Neurologic Associates
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Greensboro : Guilford Neurologic Associates
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
Greensboro : Guilford Neurologic Associates
Insulin Resistance Intervention After Stroke Trial (IRIS)
Greensboro : Guilford Neurologic Associates
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Raleigh : PMG Research of Raleigh
Heart Attack...Stroke. Are you at risk?
Winston-Salem : PMG Research of Winston-Salem Updated
Have you had a stroke? Have you experienced difficulty walking since your stroke?
View More »
Asheboro : 1160.129.32194 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Asheville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Burlington : 1160.129.32265 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Cary : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Durham : Duke University Medical Center
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Greensboro : Wake Forest University Baptist Medical Center
Aspirin in Reducing Events in the Elderly
Greensboro : US037
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Greensboro : 1160.129.32022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Greensboro : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Greenville : The Brody School of Medicine at ECU
Aspirin in Reducing Events in the Elderly
Hickory : 1160.129.32070 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hickory : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
High Point : 1160.129.32033 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jacksonville : 1160.129.32114 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kannapolis : 1160.129.32251 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Lenoir : 1160.129.32072 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Morganton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pinehurst : 1160.129.32073 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Pinehurst : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Raleigh : 1160.129.32162 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Raleigh : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Rocky Mount : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sanford : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Smithfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Statesville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Wilmington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Wilson : 1160.129.32215 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Winston-Salem : Merz Investigational Site #001009
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Winston-Salem : Guilford Neurologic Associates
Insulin Resistance Intervention After Stroke Trial
Winston-Salem : Clinical Research of Winston-Salem
Insulin Resistance Intervention After Stroke Trial
North Dakota
Fargo : 1160.129.32118 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Grand Forks : Altru Health System
Insulin Resistance Intervention After Stroke Trial
Grand Forks : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Minot : 1160.129.32220 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ohio
Akron : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Canton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Cincinnati : University of Cincinnati
Insulin Resistance Intervention After Stroke Trial
Cincinnati : Drake Rehabilitation Center
Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery
Cincinnati : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
View More »
Cleveland : MetroHealth Medical Center
Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain
Cleveland : 1160.129.32273 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Cleveland : Metrohealth Medical Center
Insulin Resistance Intervention After Stroke Trial
Cleveland : Case Western Reserve University
Insulin Resistance Intervention After Stroke Trial
Cleveland : Cleveland Clinic Foundation
Insulin Resistance Intervention After Stroke Trial
Cleveland : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Cleveland : Cleveland Clinic Foujndation
Rehabilitation of the Stroke Hand at Home
Cleveland : University Hospitals of Cleveland
Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
Columbus : The Ohio State University
AMPLATZER Cardiac Plug Clinical Trial
Columbus : The Ohio State University
Cryptogenic Stroke Study
Columbus : Ohio State University
Insulin Resistance Intervention After Stroke Trial
Columbus : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Columbus : Ohio Health Research Institute
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Dayton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fairfield : 1160.129.32257 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fairfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fairview Park : 1160.129.32061 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Gallipolis : 1160.129.32011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hudson : 1160.129.32060 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kettering : 1160.129.32183 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mansfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Marion : 1160.129.32316 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Marion : 1160.129.32158 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Miamisburg : 1160.129.32012 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sandusky : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Springfield : 1160.129.32244 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Springfield : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Toledo : 1160.129.32285 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Toledo : University of Toledo
Insulin Resistance Intervention After Stroke Trial
Toledo : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Youngstown : 1160.129.32032 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Youngstown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Zanesville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oklahoma
Oklahoma City : 1160.129.32258 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oklahoma City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oklahoma City : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Tulsa : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oregon
Bend : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Portland : Oregon Health and Science University Updated
AMES Treatment of the Impaired Leg in Chronic Stroke Patients
Portland : 1160.129.32163 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Portland : Oregon Health & Science University
Insulin Resistance Intervention After Stroke Trial
Portland : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pennsylvania
Altoona : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Beaver : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bethlehem : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Bryn Mawr : Lankenau Institute for Medical Research
Insulin Resistance Intervention After Stroke Trial
Camp Hill : 1160.129.32236 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Carnegie : 1160.129.32086 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chambersburg : 1160.129.32206 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chambersburg : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Doylestown : 1160.129.32157 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Doylestown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Elkins Park : Einstein Hospital/Moss Rehabilitation
SISTERS: Spasticity In Stroke Study - Randomized Study
Erie : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Harleysville : 1160.129.32113 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hershey : Penn Stat-Hershey Medical Center (NINDS-CRC site)
Insulin Resistance Intervention After Stroke Trial
Hershey : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Hummelstown : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Jersey Shore : 1160.129.32127 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Johnstown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lancaster : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Langhorne : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lansdale : 1160.129.32153 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mine Hill : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Penndel : 1160.129.32115 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Philadelphia : Albert Einstein Medical Center
Aspirin in Reducing Events in the Elderly
Philadelphia : 1160.129.32323 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Philadelphia : University of Pennsylvania Medical Center
GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study
Philadelphia : Temple University
Insulin Resistance Intervention After Stroke Trial
Philadelphia : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pittsburgh : University of Pittsburgh Medical Center
A Study of Modified Stem Cells in Stable Ischemic Stroke
Pittsburgh : University of Pittsburgh Health Sciences Research Center
Aspirin in Reducing Events in the Elderly
Pittsburgh : US084
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Pittsburgh : Allegheny Singer Research Institute
Insulin Resistance Intervention After Stroke Trial
Pittsburgh : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Pittsburgh : University of Pittsburgh Medical Center Presbyterian Hospital
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Scranton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sellersville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Warminster : 1160.129.32109 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
West Chester : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Yardley : 1160.129.32137 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
York : York Hospital
AMPLATZER Cardiac Plug Clinical Trial
York : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Rhode Island
Pawtucket : Memorial Hospital of Rhode Island
Aspirin in Reducing Events in the Elderly
Pawtucket : 1160.129.32224 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Pawtucket : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Providence : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Providence : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
South Carolina
Mt. Pleasant : PMG Research of Charleston Updated
Have you suffered from a heart attack or stroke?
View More »
Anderson : 1160.129.32160 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Anderson : 1160.129.32243 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Anderson : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Beaufort : 1160.129.32002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Charleston : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Columbia : US057
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Columbia : 1160.129.32050 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Florence : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Greenville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Myrtle Beach : 1160.129.32108 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
South Dakota
Rapid City : 1160.129.32267 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Rapid City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Watertown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tennessee
Bristol : PMG Research of Bristol
Heart Attack...Stroke. Are you at risk?
View More »
Chattanooga : US019
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Chattanooga : Erlanger Health care system
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Chattanooga : 1160.129.32217 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Germantown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Johnson City : 1160.129.32272 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Johnson City : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Knoxville : 1160.129.32082 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Knoxville : 1160.129.32287 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Knoxville : 1160.129.32080 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Knoxville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Memphis : University of Tennessee Health Science Center
Aspirin in Reducing Events in the Elderly
Nashville : Vanderbilt University Medical Center
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Nashville : Merz Investigational Site #001206
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Nashville : US058
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Nashville : 1160.129.32186 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Nashville : Vanderbilt
Insulin Resistance Intervention After Stroke Trial
Nashville : Vanderbilt Univiersity
Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients
Nashville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Tazewell : 1160.129.32223 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oak Ridge : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tullahoma : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Texas
Austin : 1160.129.32145 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Austin : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Austin : University Medical Center at Brackenridge
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Beaumont : 1160.129.32095 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Dallas : University of Texas Southwestern Medical Center at Dallas
Aspirin in Reducing Events in the Elderly
View More »
Dallas : 1160.129.32252 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Dallas : 1160.129.32290 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Dallas : 1160.129.32322 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Dallas : University of Texas, Southwestern
Insulin Resistance Intervention After Stroke Trial
Dallas : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Fort Worth : 1160.129.32097 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fort Worth : 1160.129.32300 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Fort Worth : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Galveston : University of TX Medical Branch
Aspirin in Reducing Events in the Elderly
Georgetown : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Grapevine : 1160.129.32105 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Grapevine : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Houston : Merz Investigational Site #001183
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Houston : US021
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Houston : 1160.129.32111 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32100 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32092 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32027 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32123 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32295 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : 1160.129.32301 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Houston : Methodist Neurological Institute
Insulin Resistance Intervention After Stroke Trial
Houston : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Houston : UT-Houston Health Science Center
Safety of Intravenous Thrombolysis for Wake-up Stroke
Houston : Baylor College of Medicine
SmartRisk Stroke Prediction by MRI of Carotid Disease
Houston : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Houston : The University of Texas Medical School
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Humble : 1160.129.32219 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Katy : 1160.129.32171 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Katy : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Kingwood : 1160.129.32211 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kingwood : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lubbock : 1160.129.32260 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
McAllen : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Mission : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Braunfels : 1160.129.32189 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
North Richland Hills : 1160.129.32177 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Odessa : 1160.129.32197 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Plano : Texas Stroke Institute
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Plano : The Heart Hospital Baylor
AMPLATZER Cardiac Plug Clinical Trial
Plano : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Round Rock : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
San Antonio : UT Health Science Center at San Antonio
Aspirin in Reducing Events in the Elderly
San Antonio : 1160.129.32187 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
San Antonio : 1160.129.32238 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
San Antonio : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sealy : 1160.129.32288 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seguin : 1160.129.32191 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sugar Land : 1160.129.32068 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Sugar Land : 1160.129.32040 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
The Woodlands : 1160.129.32319 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Tomball : 1160.129.32091 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Tomball : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tyler : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Waco : 1160.129.32093 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Whitney : 1160.129.32175 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Utah
Provo : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Salt Lake City : 1160.129.32121 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Salt Lake City : 1160.129.32034 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Salt Lake City : University of Utah
Insulin Resistance Intervention After Stroke Trial
Salt Lake City : Western Institute for Biomedical Research
SmartRisk Stroke Prediction by MRI of Carotid Disease
Vermont
Burlington : University of Vermont
Insulin Resistance Intervention After Stroke Trial
Virginia
Burke : 1160.129.32166 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Charlottesville : University of Virginia
Insulin Resistance Intervention After Stroke Trial
Charlottesville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Chesapeake : 1160.129.32004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Danville : 1160.129.32067 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Danville : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Falls Church : 1160.129.32146 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Falls Church : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Harrisonburg : James Madison University and Rockingham Memorial Hospital
The Passy Muir Swallowing Self Training Device to Enhance Recovery Post Stroke
Lynchburg : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Manassas : 1160.129.32200 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Manassas : 1160.129.32328 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Manassas : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Midlothian : 1160.129.32279 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Norfolk : Sentara Medical Group
Insulin Resistance Intervention After Stroke Trial
Norfolk : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Richmond : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Winchester : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Washington
Lynnwood : Clinical Trials of America, Inc
Are you experiencing deficits post ischemic stroke?
View More »
Bellevue : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Burien : 1160.129.32062 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Everett : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Port Orchard : 1160.129.32227 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Redmond : Cerevast Therapeutics, Inc. Updated
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
Seattle : 1160.129.32241 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seattle : Swedish Medical Center, Cherry Hill Campus
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Spokane : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Tacoma : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
West Virginia
Wisconsin
Green Bay : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
La Crosse : 1160.129.32308 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Madison : University of Wisconsin
Insulin Resistance Intervention After Stroke Trial
Milwaukee : US097
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Milwaukee : 1160.129.32325 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Milwaukee : 1160.129.32041 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Milwaukee : 1160.129.32088 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Milwaukee : 1160.129.32058 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Milwaukee : Medical College of Wisconsin
Insulin Resistance Intervention After Stroke Trial
Wausau : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Argentina
Australia
Bedford Park : Flinders Medical Centre
Insulin Resistance Intervention After Stroke Trial
Box Hill : Box Hill Hospital (Eastern Health)
Insulin Resistance Intervention After Stroke Trial
Camperstown : Royal Prince Alfred
Insulin Resistance Intervention After Stroke Trial
Clayton : AU006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Footscray : Western Hospital (University of Melbourne)
Insulin Resistance Intervention After Stroke Trial
View More »
Gosford : AU004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Heidelberg : Heidelberg Repatriation Hospital, Melbourne
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Heidelberg Heights : Austin Health (National Stroke Research Institute)
Insulin Resistance Intervention After Stroke Trial
Melbourne : AU002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Melbourne : AU001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
New Castle : AU003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
New Lambton Heights : John Hunter Hospital (University of Newcastle)
Insulin Resistance Intervention After Stroke Trial
Parkville : Royal Melbourne Hospital
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Parkville : Royal Melbourne Hospital
Insulin Resistance Intervention After Stroke Trial
Perth : Royal Perth
Insulin Resistance Intervention After Stroke Trial
Austria
Graz : AT003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Graz : Universitätsklinikum für Neurologie
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Innsbruck : AT004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Innsbruck : 1160.136.34002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Linz : O.O. Landes-Nervenklinik Wagner-Jauregg
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
View More »
Linz : AT001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Linz : 1160.136.34001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Neupölla : 1160.136.34005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Oberwart : 1160.136.34008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Salzburg : Christian-Doppler-Klinik Salzburg,Universitätsklinik für Neurologie
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Vienna : Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner-Spital
SISTERS: Spasticity In Stroke Study - Randomized Study
Wien : Merz Investigational Site #043003
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Zirl : Landeskrankenhaus Hochzirl
SISTERS: Spasticity In Stroke Study - Randomized Study
Belarus
Grodno : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Minsk : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Vitebsk : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Belgium
Bruxelles : Clin. Univ. UCL Saint Luc
SISTERS: Spasticity In Stroke Study - Randomized Study
Dendermonde : AZ Sint Blasius Hospital, Department of Vascular Surgery Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Gent : Universitair Ziekenhuis Gent
SISTERS: Spasticity In Stroke Study - Randomized Study
Ghent : Drug Research Unit Ghent
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
Leuven : Universitaire Ziekenhuizen Leuven, campus Pellenberg
SISTERS: Spasticity In Stroke Study - Randomized Study
View More »
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Brazil
Bulgaria
Burgas : 1160.136.36004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Kazanlak : 1160.136.36002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Pleven : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Plovdiv : 1160.136.36008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Rousse : 1160.136.36005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
View More »
Sevlievo : 1160.136.36001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sliven : 1160.136.36013 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sofia : 1160.136.36012 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sofia : 1160.136.36011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sofia : 1160.136.36014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sofia : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Stara Zagora : 1160.136.36009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Yambol : 1160.136.36006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Canada
Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Brampton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Burlington : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Calgary : CA001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
View More »
Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Cambridge : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chicoutimi : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Cornwall : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Edmonton : CA004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Edmonton : University of Alberta
Insulin Resistance Intervention After Stroke Trial
Edmonton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Gatineau : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Greenfield Park : Merz Investigational Site #001201
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Greenfield Park : Hôpital Charles LeMoyne
Insulin Resistance Intervention After Stroke Trial
Greenfield Park : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Halifax : Merz Investigational Site #001204
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Halifax : QE II Health Sciences Centre
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Halifax : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Hamilton : Hamilton Health Sciences Corporation-General Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Hamilton : Hamilton Health Sciences Corporation-Henderson Site
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Hamilton : Hamilton Health Sciences Corporation-McMaster Site
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Hamilton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Hamilton : Health Science Centre, McMaster University
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
Hamilton : Saint Joseph's Healthcare
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kelowna : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Kitchener : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Laval : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Lethbridge : Center for Neurologic Research
Insulin Resistance Intervention After Stroke Trial
Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Levis : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
London : Robarts Research Institute
Insulin Resistance Intervention After Stroke Trial
London : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Longueuil : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Mississauga : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Moncton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Montreal : CHUM-Centre de recherche, Hôpital Notre-Dame
Insulin Resistance Intervention After Stroke Trial
Montreal : McGill-Jewish General
Insulin Resistance Intervention After Stroke Trial
Montreal : McGill-Montreal General
Insulin Resistance Intervention After Stroke Trial
Montreal : Montreal General Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Montreal : SMBD Jewish General Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Montreal : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
New Westminster : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Newmarket : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
North York : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Oshawa : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Ottawa : Ottawa Hospital-General Campus
Insulin Resistance Intervention After Stroke Trial
Ottawa : Ottawa Hospital-General Campus
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Ottawa : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Penticton : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Quebec : IUCPQ
Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
Quebec : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Quebec City : Centre Hospitalier Affilie Universitaire de Quebec
Insulin Resistance Intervention After Stroke Trial
Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saint John : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Saint-charles-borromee : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saint-georges : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Saint-jerome : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sarnia : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saskatoon : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Scarborough : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. John's : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St-lambert : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Sudbury : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Surrey : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Terrebonne : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Thetford Mines : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Thunder Bay : Intermountain Research Consultants
Insulin Resistance Intervention After Stroke Trial
Thunder Bay : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Toronto : Sunnybrook Health Sciences Centre
Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A
Toronto : CA012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Toronto : CA002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Toronto : 1160.129.06031 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Toronto : St. Michael's Hospital
Insulin Resistance Intervention After Stroke Trial
Toronto : University Health Network - Toronto General Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Toronto : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Val D'or : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Vancouver : St-Paul's Hospital
Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
Vancouver : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Victoria : CA005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Victoria : Vancouver Island Health Research Centre
Insulin Resistance Intervention After Stroke Trial
Victoria : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Windsor : Research Site
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Winnipeg : Merz Investigational Site #001202
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
China
Beijing : Weiwei Zhang
Chinese Assessment for Vinpocetine In Neurology
Guangzhou : Zhujiang Hospital, Southern Medical University
Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke
Hong Kong : Queen Mary Hospital
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Hong-Kong : Prince of Wales Hospital
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
Shatin : The Prince of Wales Hospital
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Colombia
Croatia
Zagreb : Department of Neurology, University Hospital Sestre Milosrdnice
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Czech Republic
Brno : Merz Investigational Site #420029
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Brno : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Hradec Kralové : Fakultní nemocnice Hradec Králové
Effect of F2695 on Functional Recovery After Ischemic Stroke
Jihlava : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Olomouc : Merz Investigational Site #420028
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
View More »
Ostrava - Vítkovice : Vítkovická nemocnice a.s.
Effect of F2695 on Functional Recovery After Ischemic Stroke
Ostrava-Poruba : Merz Investigational Site #420024
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Ostrava-Vitkovice : Merz Investigational Site #420031
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Plzen - Lochotin : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Praha : Merz Investigational Site #420030
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Rychnov nad Kneznou : Merz Investigational Site #420047
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Denmark
Aarhus : DK001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Copenhagen : Rigshospitalet
GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study
Copenhagen NV : DK004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
El Salvador
Estonia
Tallin : 1160.136.38001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Tallinn : EE002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Tallinn : EE004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Tallinn : EE003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Tallinn : 1160.136.38002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
View More »
Tartu : EE001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Finland
Helsinki : FI001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Turku : FI003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
France
Arbois : 1160.136.13059 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Avignon : 1160.136.13060 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Bagnols sur Ceze : 1160.136.13035 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Bersée : 1160.136.13015 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Besancon : FR004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
View More »
Besancon : 1160.136.13039 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Beziers : 1160.136.13036 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Beziers : 1160.136.13040 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Bordeaux : FR013
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Bordeaux : 1160.136.13004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Bordeaux : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Bourg-en-Bresse : FR003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Broglie : 1160.136.13045 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Bruay la Buissière : 1160.136.13054 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Caen : FR015
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Cannes : 1160.136.13014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Chateauroux : 1160.136.13046 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Cherbourg : 1160.136.13025 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Clermont Ferrand : 1160.136.13017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Clermont-Ferrand : Hôpital Gabriel Montpied
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Evecquemont : 1160.136.13063 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Garches : Merz Investigational Site #033018
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Le Coudray : 1160.136.13058 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Levallois Perret : 1160.136.13010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Libourne : 1160.136.13008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Libourne : 1160.136.13044 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lille : Merz Investigational Site #033046
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Lille : FR014
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Limoges : FR012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Limoges : 1160.136.13078 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lyon : Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Many locations :
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Marseille : 1160.136.13075 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Marseille cedex 5 : 1160.136.13047 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Mondelange : 1160.136.13019 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montargis : 1160.136.13056 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montauban : 1160.136.13053 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montauban : 1160.136.13013 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montfermeil : 1160.136.13048 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montfermeil : 1160.136.13001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Montpellier : Hôpital Gui de Chauliac
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Montpellier : 1160.136.13072 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Neuilly sur Seine : 1160.136.13064 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Nice : FR010
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Nimes : 1160.136.13018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Orléans : 1160.136.13065 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Paris : Hôpital Bichat-Claude Bernard
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Paris : FR009
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Paris : FR001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Paris : BICHAT HOSPITAL Departement of Neurology
Treat Stroke to Target
Paris : BICHAT HOSPITAL Department of neurology and stroke center
Treat Stroke to Target
Paris Cedex 13 : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Perpignan : FR007
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Rennes : Merz Investigational Site #033024
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Rennes Cedex : 1160.136.13066 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Saint-Yrieix-la-Perche : 1160.136.13026 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Strasbourg : 1160.136.13067 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Toulouse : Hôpital Rangueil
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Toulouse : Hôpital Purpan
Effect of F2695 on Functional Recovery After Ischemic Stroke
Toulouse : FR016
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Toulouse : 1160.136.13023 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Tourcoing : 1160.136.13003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Tours : 1160.136.13043 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Valence : 1160.136.13050 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Vihiers : 1160.136.13021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Wattrelos : 1160.136.13038 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Georgia
Germany
Altenburg : Klinikum Altenburger Land
Insulin Resistance Intervention After Stroke Trial
Altenburg : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Bad Neustadt : Neurologische Klinik
Insulin Resistance Intervention After Stroke Trial
Bayreuth : Department of Neurology, Klinikum Hohe Warte
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Beelitz-Heilstätten : Merz Investigational Site #049022
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
View More »
Beelitz-Heilstätten : Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik
SISTERS: Spasticity In Stroke Study - Randomized Study
Bennewitz :
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]
Berlin :
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]
Berlin : Merz Investigational Site #049127
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Berlin : DE002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Berlin : 1160.136.02001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : 1160.136.02016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : 1160.136.02020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : 1160.136.02039 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : 1160.136.02021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : 1160.136.02036 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Berlin : Ihre-Radiologen.de Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Berlin : Charite University (Center for Stroke Research Berlin CSB & NeuroCure Clinical Research Center NCRC)
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Berlin : Vivantes Neukölln Neurologie
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Berlin : Vivantes Auguste Viktoria Klinikum Neurologie
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Berlin : Unfallkrankenhaus Berlin Neurologie
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Berlin : Charite Campus Benjamin Franklin, Dept. of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Bonn : Ambulantes Neurologisches Rehabilitationszentrum
SISTERS: Spasticity In Stroke Study - Randomized Study
Braunschweig : Klinikum Braunschweig, Department of Cardiothoracic Surgery
Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit
Bremen : 1160.136.02042 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Burgau : Therapiezentrum Burgau
SISTERS: Spasticity In Stroke Study - Randomized Study
Celle : Department of Neurology, Allgemeines Krankenhaus Celle
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Chemnitz : Department of Neurology, Klinikum Chemnitz gGmbH
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Dessau-Roßlau : 1160.136.02017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Detmold : 1160.136.02041 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Dinslaken : 1160.136.02014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Dortmund : 1160.136.02033 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Dortmund : Klinikum Dortmund GmbH Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Dresden : DE001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Dresden : University Hospital-Dresden
Insulin Resistance Intervention After Stroke Trial
Dresden : Department of Neurology, Universitaetsklinikum Carl Gustav Carus
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Duesseldorf : University Duesseldorf/Heinrich-Heine University
Insulin Resistance Intervention After Stroke Trial
Duesseldorf : Heinrich-Heine-University Duesseldorf, Dept. of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Düsseldorf : Merz Investigational Site #049071
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Erlangen : Erlangen University Clinic
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Erlangen : University of Erlangen
Insulin Resistance Intervention After Stroke Trial
Essen : Essen University Clinic
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Essen : Alfried Krupp Hospital
Insulin Resistance Intervention After Stroke Trial
Frankfurt : CardioVascular Center Frankfurt, Sankt Katharinen
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Frankfurt : University Hospital Frankfurt
Insulin Resistance Intervention After Stroke Trial
Frankfurt : CardioVascular Center Frankfurt Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Frankfurt (Oder) : Klinikum Frankfurt (Oder) Neurologie
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Freiburg : Freiburg University
Insulin Resistance Intervention After Stroke Trial
Giessen : University of Giessen-Marburg Dept. of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Griefswald : Ernst-Moritz-Arndt-University Greifswald
Insulin Resistance Intervention After Stroke Trial
Halle : Martin-Luther-Universitaet Halle-Wittenberg
Insulin Resistance Intervention After Stroke Trial
Hamburg : Merz Investigational Site #049079
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Hamburg : University Medical Center Hamburg-Eppendorf
Insulin Resistance Intervention After Stroke Trial
Hamburg : Hamburg University Cardiovascular Center Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Hamburg : Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Hannover : Hannover Medical School, Clinic for Cardiac, Thoracic, Transplantation and Vascular Surgery
Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit
Heidelberg : Heidelberg University Clinic
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Heidelberg : University Heidelberg
Insulin Resistance Intervention After Stroke Trial
Ingolstadt : 1160.136.02051 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Jena : Friedrich Schiller-University Jena
Insulin Resistance Intervention After Stroke Trial
Jena : Department of Neurology, Universitaetsklinikum Jena
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Kassel : 1160.136.02022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Kempen : 1160.136.02009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Kiel : Merz Investigational Site #049304
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Kirchzarten : 1160.136.02030 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Leipzig : DE003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Leipzig : Leipzig University Clinic
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Leipzig : Herzzentrum and Park-Krankenhaus Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Leipzig : Department of Neurology, Universitaetsklinikum Leipzig
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Leipzig : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Leverkusen : 1160.136.02026 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lübeck : DE022
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Ludwigsburg : 1160.136.02008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Luebben :
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]
Mainz : 1160.136.02053 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Mainz : University Hospital Mainz
Insulin Resistance Intervention After Stroke Trial
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Markkleeberg : 1160.136.02012 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Muenchen : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Muenster : University Hospital Muenster
Insulin Resistance Intervention After Stroke Trial
Muenster : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Mühldorf : 1160.136.02007 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Mühlhausen / Thürigen : Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
München : Merz Investigational Site #049072
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
München : Merz Investigational Site #049148
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
München : 1160.136.02010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
München : Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Munich : Klinikum der Universitat Muenchen
Insulin Resistance Intervention After Stroke Trial
Munich : Site 01: Department of Neurology, TU Munich Updated
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Munich : Städtisches Klinikum München GmbH Klinikum Neuperlach Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Munster : Munster University Clinic
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Münster : Universitätsklinikum Münster
Effect of F2695 on Functional Recovery After Ischemic Stroke
Münster : Site 03: Universitätsklinikum Münster Updated
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Numbrecht : Rhein-Sieg-Klinik Dr. Becker Klinikgesellschaft
SISTERS: Spasticity In Stroke Study - Randomized Study
Nürnberg : 1160.136.02004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Potsdam : 1160.136.02031 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Regensburg : Merz Investigational Site #049303
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Regensburg : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Rostock : DE025
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Tübingen : Site 04: Universitätsklinikum Tübingen, Klinik für Allgemeine Neurologie Updated
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Tuebingen : Department of Neurology, University Tuebingen
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Tutzing : Site 02: Benedictus Krankenhaus Tutzing GmbH u. Co. KG Updated
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Ulm : 1160.136.02005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Ulm : University of Ulm
Insulin Resistance Intervention After Stroke Trial
Ulm : University of Ulm, Department of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Villingen-Schwenningen : 1160.136.02037 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Vöhringen : 1160.136.02029 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Wittenberg : 1160.136.02011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Würzburg : Merz Investigational Site #049302
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Hong Kong
Hong Kong : HK002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Hong Kong : HK001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Hong Kong : Queen Mary Hospital
Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
Shatin : Prince of Wales Hospital
Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke
Hungary
Balassagyarmat : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Budapest : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Debrecen : Updated
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Debrecen : Updated
BOTOX® Treatment in Pediatric Upper Limb Spasticity
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
India
Bangalore : St. John's Medical College
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
Chandigarh : IN004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Guntur : IN009
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Hyderabad : IN003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Hyderabad : Care Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
View More »
Hyderabad : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Ludhiana : IN007
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
New Delhi : Sir Ganga Ram Hospital
PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
New Delhi : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Pune : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Indonesia
Israel
Beer Sheva : Soroka Medical Center
Insulin Resistance Intervention After Stroke Trial
Haifa : Rambam Medical Center
Electroencephalograph for Detection of Acute Ischemic Stroke
Haifa : Bnai-Zion Medical Center
Insulin Resistance Intervention After Stroke Trial
Haifa : B'nai Zion Medical Center
Insulin Resistance Intervention After Stroke Trial
Haifa : Rambam Medical Center
Insulin Resistance Intervention After Stroke Trial
View More »
Holon : Wolfson Medical Center
Insulin Resistance Intervention After Stroke Trial
Jerusalem : Hadassah Medical Organization
Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Petach Tikva : Rabin Medical Center-Golda Campus
Insulin Resistance Intervention After Stroke Trial
Ramat Gan : Sheba Medical Center
Insulin Resistance Intervention After Stroke Trial
Tel Aviv : Tel Aviv Medical Center
Insulin Resistance Intervention After Stroke Trial
Italy
Costa Masnaga : Centro di Riabilitazione "Villa Beretta"
SISTERS: Spasticity In Stroke Study - Randomized Study
Cotignola : Gruppo Villa Maria, Villa Maria Cecilia Hospital
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Cotignola : Villa Maria Cecilia Hospital Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Imperia : IT004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Laquila : University of Laquila
Insulin Resistance Intervention After Stroke Trial
View More »
Mercogliano : Casa di Cura Privata "Montevergine" S.p.A.
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Messina : Merz Investigational Site #039006
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Milan : University Vita Salute San Raffaele
Insulin Resistance Intervention After Stroke Trial
Mirano : Ospedale Civile di Mirano, Unità di Cardiologia
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Mirano : Mirano Hospital Updated
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Modena : IT012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Pavia : IRCCS FONdazione Istituto Neurologico C. Mondino
Insulin Resistance Intervention After Stroke Trial
Pavia : Fondazione Salvatore Maugeri Clinica del lavoro e della riabilitazione IRCSS
SISTERS: Spasticity In Stroke Study - Randomized Study
Perugia : University of Perugia
Insulin Resistance Intervention After Stroke Trial
Roma : Merz Investigational Site #039011
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Roma : Merz Investigational Site #039012
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Roma : University of Rome (S. Andrea Hospital)
Insulin Resistance Intervention After Stroke Trial
Rome : IT001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Rome : IT005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Rome : University of Rome La Sapienza
Insulin Resistance Intervention After Stroke Trial
Rome : Sacred Heart Catholic University
Insulin Resistance Intervention After Stroke Trial
Verona : IT011
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Vibo Valentia : Jazzolino Hospital
Insulin Resistance Intervention After Stroke Trial
Japan
Akita : JP006
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Fukuoka : JP021
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Hiroshima : JP018
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Isesaki : JP007
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Kagoshima : JP024
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
View More »
Kawasaki : JP011
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Kobe : JP015
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Kumamoto : JP022
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Nagoy : JP012
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Nishinomiya : JP026
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Okayama : JPO17
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Sapporo : JP001
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Sapporo,Hokkaido : JP002
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Sendai : JP004
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Shibata : JP005
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Suita : JP014
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Tokushima : JP020
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Tokyo : JP009
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Toyota : JP013
Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke
Kazakhstan
Almaty : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Korea, Republic of
Ansan : Korea University Ansan Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Ansan : Korea University Ansan Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Ansan-Si : KR013
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Anyang : Hallym University Sacred Heart Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Anyang : Department of Neurology, Hallym University Sacred Heart Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
View More »
Anyang : Hallym Univesity Sacred Heart Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Anyang City : KR003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Anyang-si : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Bucheon : Soonchunhyang University Bucheon Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : KR006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Busan : 1160.129.11008 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Busan : 1160.129.11029 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Busan : 1160.129.11011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Busan : 1160.129.11017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Busan : 1160.129.11007 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Busan : Inje University Pusan Paik Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : Pusan National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : Dong-A University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : Inje Univercity Heaundae Paik Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : Kosin University Gospel Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Busan : Department of Neurology Pusan National University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Busan : Department of Neurology Colleage of Medicine Dong-A University
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Busan : Department of Neurology, College of Medicine Inje University, Paik Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Busan : Dong-A University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Changwon : Chang Won Fatima hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Changwon : Samsung changwon Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Cheonan : Soonchunhyang University Cheonan Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Cheongju : Chungbuk National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Chuncheon : Kangwon National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Daegu : KR011
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Daegu : 1160.129.11019 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Daegu : 1160.129.11024 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Daegu : 1160.129.11013 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Daegu : 1160.129.11014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Daegu : Daegu Fatima Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Daegu : Keimyung University Dongsan Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Daegu : Department of Neurology, Yeungnam University School of Medicine
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Daegu : Department of Neurology, Dongsan Medical Center, Keimyung University School of Medicine
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Daegu : Dongsan Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Daejeon : Chungnam National University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Daejon : Eulji University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Daejon : Department of Neurology Konyang University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Deagu : Deagu Catholic University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Deagu : Dongsan Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Deagu : Yeungnam University Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Deagu : Kyungpook National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Deajeon : Chungnam National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Deajeon : Deajeon St.Mary's Hospital, The Catholic University of Korea
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Goyang : Inje University Ilsan Paik Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Goyang : Dongguk University International Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Goyang : Dongguk University International Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Goyang-si : National Health Insurance Corporation Ilsan Hoapital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Guri : Hanyang University Guri Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Guri : Hanyang University Guri Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Gwangju : 1160.129.11016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Gwangju : Chonnam National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
GwangJu : Chosun University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Gwangju : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
GwangJu : Department of Neurology, Chonnam National University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Gwangju : Department of Neurology, Chosun University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Gwangju : Chosun University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Gyeonggi-do : Kwandong University College of Medicine Myongji Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Gyeonggi-do : Kwandong University College of Medicine Myongji Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Iksan : 1160.129.11006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Iksan : Wonkwang University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
In Cheon : KR002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Incheon : Gachon University Gil Hoapital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Incheon : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Incheon : Department of Neurology, Inha University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Inchon : Inha University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Inchon : Inha University Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Jeju : 1160.129.11020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jeonju : 1160.129.11022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jeonju-si : Chonbuk National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Jinju : 1160.129.11021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Jinju : Gyeongsang National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Koyang-shi : Department of Neurology, National health insurance corporation ilsan Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Kwangju : KR010
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
Mok-dong : Ewha Womans University Mokdong Hospital
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
Pusan : Wallace Memorial Baptist Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seocho-Gu : Seoul St. Mary's Hospital
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
Seongnam : KR008
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seongnam : 1160.129.11010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seongnam : Seoul National University Bundang Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seongnam-si : Bundang Medical Center, CHA University
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seongnam-si : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Seoul : Updated
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Seoul : Updated
BOTOX® Treatment in Pediatric Upper Limb Spasticity
Seoul : KR009
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seoul : KR001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seoul : KR005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seoul : KR012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seoul : KR004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Seoul : 1160.129.11001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11023 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11025 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11012 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11028 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : 1160.129.11004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Seoul : National Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Ewha Womans University Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : St. Mary's Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Korea University Guro Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Korea University Anam Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Gangnam Severance Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Seoul St.Mary's Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Seoul Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Inje University Sanggye Paik Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Kyung Hee University Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Seoul National University Borame Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Asan Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Kangdong Sacred Heart Hospital, Hallym University
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Soonchunhyang University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Hangang Sacred Heart Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Kangbuk Samsung Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Severance Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Kangnam Sacred Heart Hospital, Hallym University College of Medicine
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Eulji Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Konkuk Univ. Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Chung-Ang University Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Seoul National University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Hanyang University Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Seoul : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Seoul : Department of Neurology St. Mary's Hospital, Catholic University
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, National Medical Center
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Kyung Hee University, College of Medicine
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Severance Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology Seoul National University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, University of Ulsan,Asan Medical Center
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Hallym University Medical Center
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology,Sanggye Paik Hospital, Inje University College of Medicine
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Korean University Guro hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology Kyung Hee University East-West Neo Medical Center
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Ewha Womans University Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology, Samsung Medical Center
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Department of Neurology Gangnam Severance Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Seoul : Severance Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : Asan Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : Konkuk Univ. Hospital
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : KyungHee University Medical Center
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Seoul : Samsung Medical Center, Sungkyunkwan University School of Medicine
The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study
Suwon : 1160.129.11005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Suwon : Ajou University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Suwon : St. Vincent's hospital
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
Uijeongbu : Uijeongbu St. Mary's Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Ulsan : 1160.129.11027 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ulsan : Ulsan University Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Wonju : Wonju Christian Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Wonju : Department of Neurology, Wonju Christian Hospital
The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
Wonju-si : KR007
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Yangsan : 1160.129.11015 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Yeongdeungpo-Gu : Yeoudo St. Mary's hospital
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
Latvia
Malaysia
Kuala Lumpur : Hospital: University Malaya
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
Mexico
Netherlands
Norway
Arendal : 1160.136.16002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Fornebu : 1160.136.16001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Kongsvinger : 1160.136.16004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Levanger : Levanger Hospital
Norwegian Constraint-Induced (CI) Therapy Multisite Trial
Lillehammer : 1160.136.16005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
View More »
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
RUD : 1160.136.16003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Stavern : Vestfold Klinikk Fysikalske medisin og rehabilitering, Kysthospital
Norwegian Constraint-Induced (CI) Therapy Multisite Trial
Tromsø : 1160.136.16006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Tromsø : University Hospital of North Norway
Norwegian Constraint-Induced (CI) Therapy Multisite Trial
Trondheim : Trondheim University Hospital
Norwegian Constraint-Induced (CI) Therapy Multisite Trial
Philippines
Manila : PH003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Manila : Manila Doctors Hospital
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Manila : University of Santo Tomas
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Pasig : The Medical City
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Pasig City : PH001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
View More »
Quezon City : PH002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Quezon City : St. Luke's Medical Center
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Poland
Gdansk : Merz Investigational Site #048057
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Krakow : Jagellonian University, College of Medicine, Institute of Cardiology, University Hospital
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
Krakow : Merz Investigational Site #048031
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Krakow : Merz Investigational Site #048054
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Lodz : Merz Investigational Site #048022
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
View More »
Lublin : Merz Investigational Site #048051
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Lublin : PL005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Olsztyn : Merz Investigational Site #048032
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Poznan : Merz Investigational Site #048053
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Sandomierz : PL006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Warsaw : Institute of Psychiatry and Neurology, Dept. of Neurology
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Warszawa : Merz Investigational Site #048056
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Warszawa : Merz Investigational Site #048023
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Warszawa : Merz Investigational Site #048052
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Warszawa : Merz Investigational Site #048033
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Warszawa : Merz Investigational Site #048055
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Warszawa : PL001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Warszawa : PL002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Wiązowna : Updated
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Wiązowna : Updated
BOTOX® Treatment in Pediatric Upper Limb Spasticity
Portugal
Almada : 1160.136.17005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Covilhã : 1160.136.17006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Évora : 1160.136.17013 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Faro : 1160.136.17016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lisboa : 1160.136.17010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
View More »
Lisboa : 1160.136.17002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lisboa : Centro Hospitalar de Lisboa Central, Servico de Neurologia
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Porto : 1160.136.17009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Setúbal : 1160.136.17011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Puerto Rico
San Juan : University of Puerto Rico
Insulin Resistance Intervention After Stroke Trial
Romania
Russian Federation
Barnaul : 1160.129.33024 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chelyabinsk : 1160.129.33018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Chita : 1160.129.33010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Dzerjinskiy : 1160.129.33029 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ekaterinburg : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
View More »
Ekaterinburg : 1160.129.33027 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Irkutsk : 1160.129.33016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Izhevsk : 1160.129.33006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Kazan : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Kemerovo : 1160.129.33009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Krasnoyarsk : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Krasnoyarsk : Merz Investigational Site #007010
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Krasnoyarsk : 1160.129.33017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Moscow : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Moscow : Merz Investigational Site #007011
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Moscow : 1160.129.33021 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Moscow : 1160.129.33020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Novosibirsk : 1160.129.33002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Omsk : 1160.129.33022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Perm : 1160.129.33001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Ryazan : 1160.129.33028 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Samara : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Samara : 1160.129.33015 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Saratov : 1160.129.33005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Petersburg : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
St. Petersburg : Merz Investigational Site #007009
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
St. Petersburg : 1160.129.33003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
St. Petersburg : 1160.129.33004 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Stavropol : Merz Investigational Site #007012
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Tomsk : Nycomed Investigational Site
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Vladivostok : 1160.129.33011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program - Second and Third Phases
Serbia
Belgrade : Clinical Center of Serbia, Clinic for Vascular and Endovascular Surgery
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Belgrade : Special Hospital for Cerebrovascular Diseases "Sveti Sava"
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Kragujevac : Clinical Center Kragujevac, Center for Radiology Diagnostic
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Niš : Clinical Center Niš, Center of Radiology
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Novi Sad : Clinical Center of Vojvodina, Center for Radiology
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Singapore
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
Singapore : SG002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Singapore : SG001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Slovakia
Banská Bystrica : Neurology Clinic Hospital with Policlinic of F.D. Roosevelt
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Bratislava : I. Neurology Clinic, University Hospital Bratislava
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Martin : Radiology Clinic, University Hospital Martin
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Nitra : Neurology Clinic, Faculty Hospital Nitra
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
View More »
Ružomberok : Neurology Clinic, Central Military Faculty Hospital
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Slovenia
Celje : 1160.136.42001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Ljubljana : 1160.136.42002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
South Africa
Spain
Albacete : ES010
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Alcazar de San Juan : ES012
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Badalona : Hospital Universitario Germans Trias i Pujol
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Badalona : Hospital Germans Trias i Pujol
Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours
Badalona - Barcelona : Fundació Privada Institut de Neurorehabilitació Guttmann
SISTERS: Spasticity In Stroke Study - Randomized Study
View More »
Barcelona : Hospital General Vall d'Hebron, Barcelona
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Barcelona : ES003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Barcelona : Hospital Clinic
Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours
Barcelona : Hospital Universitario Vall D'Hebron
Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours
Barcelona : 1160.136.03009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Barcelona : Hospital Vall d'Hebron
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Barcelona : Hospital Vall d'Hebron
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Bilbao : 1160.136.03022 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Casar de Caceres : 1160.136.03027 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Donostia-San Sebastian : 1160.136.03017 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
El Palmar - Murcia : 1160.136.03005 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Girona : ES004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Girona : Hospital Universitari de Girona
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Granada : 1160.136.03031 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Jerez de la Frontera - Cádiz : 1160.136.03035 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
L´Hospitalet de Llobregat : Hospital Universitario de Bellvitge
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Las Palmas de Gran Canaria : 1160.136.03020 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
León : 1160.136.03039 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Lugo : ES013
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Lugo : 1160.136.03018 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : Hospital Universitario Ramón y Cajal
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Madrid : Merz Investigational Site #034027
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Madrid : ES011
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Madrid : 1160.136.03016 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : 1160.136.03033 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : 1160.136.03028 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : 1160.136.03026 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : 1160.136.03011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : 1160.136.03002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Madrid : Hospital Universitario La Paz
SISTERS: Spasticity In Stroke Study - Randomized Study
Majadahonda : Merz Investigational Site #034028
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Malaga : 1160.136.03003 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Malaga : Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga
Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
Málaga - Marbella : 1160.136.03025 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Marbella . Málaga : 1160.136.03024 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Palma de Mallorca : 1160.136.03036 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Pamplona : 1160.136.03045 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
San Juan de Alicante : 1160.136.03030 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sant Joan Despi : 1160.136.03040 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Santiago de Compostela : 1160.136.03012 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Santiago de Compostela : 1160.136.03019 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sevilla : Merz Investigational Site #034030
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Sevilla : Merz Investigational Site #034026
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Sevilla : 1160.136.03001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Terrassa : Merz Investigational Site #034029
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Valencia : 1160.136.03038 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Valencia : 1160.136.03034 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Valencia : 1160.136.03010 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Valladolid : ES006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Vigo : 1160.136.03032 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Vigo : 1160.136.03037 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Sweden
Falun : 1160.136.19006 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Göteborg : 1160.136.19011 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Malmö : 1160.136.19001 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Stockholm : 1160.136.19002 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
View More »
Stockholm : Karolinska Hospital
Safety Study of the Rapid System for Acute Ischemic Stroke
Umeå : 1160.136.19009 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Västerås : 1160.136.19014 Boehringer Ingelheim Investigational Site Updated
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
Switzerland
Barmelweid : Schlafklinik Barmelweid AG
Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy
Bellinzona : Ospedale San Giovanni
Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy
Bern : Inselspital, Universitätsklinik für Pneumologie
Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy
Lausanne : CH001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Lugano : Neurocenter of Southern Switzerland, Ospedale Civico
Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy
View More »
Zurich : Neurology, Stroke Unit, University Hospital
Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy
Taiwan
Kaohsiung : TW001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Kaohsiung : TW003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Kaohsiung : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Taichung : TW006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Taichung : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
View More »
Taichung : China Medical University Hospital
The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke
Tainan : TW005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Tainan : TW008
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Taipei : TW002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Taipei : TW009
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Taipei : TW007
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Taipei : Pfizer Investigational Site Updated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Taoyuan : TW004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Thailand
Bangkok : TH006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Bangkok : TH002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Bangkok : TH003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Chiang Mai : TH005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Pathumthani : TH001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Ukraine
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
United Kingdom
Aberdeen : Aberdeen Royal Infirmary
Insulin Resistance Intervention After Stroke Trial
Airdrie : Monklands Hospital
Insulin Resistance Intervention After Stroke Trial
Ashford : William Harvey Hospital
Insulin Resistance Intervention After Stroke Trial
Ashington : Wansbeck General Hospital
Insulin Resistance Intervention After Stroke Trial
Bath : Royal United Hospital
Insulin Resistance Intervention After Stroke Trial
View More »
Blackpool : Blackpool Victoria Hospital
Insulin Resistance Intervention After Stroke Trial
Bournemouth : Royal Bournemouth
Insulin Resistance Intervention After Stroke Trial
Cambridge : Addenbrookes Foundation NHS Trust (Cambridge)
Insulin Resistance Intervention After Stroke Trial
Cheshire : Countess of Chester Foundation Trust
Insulin Resistance Intervention After Stroke Trial
Christchurch : GB004
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Dewsbury : Dewsbury District Hospital
Insulin Resistance Intervention After Stroke Trial
Dundee : GB010
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Essex : Southend University Hospital
Insulin Resistance Intervention After Stroke Trial
Exeter : GB002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Exeter : Devon PCT
Insulin Resistance Intervention After Stroke Trial
Exeter : Royal Devon and Exeter
Insulin Resistance Intervention After Stroke Trial
Gateshead : Queen Elizabeth Hospital Gateshead
Insulin Resistance Intervention After Stroke Trial
Glasgow : GB009
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Glasgow : GB007
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Glasgow : Southern General Hospital
Insulin Resistance Intervention After Stroke Trial
Glasgow : Stobhill Hospital
Insulin Resistance Intervention After Stroke Trial
Glasgow : Glasgow Royal Infirmary
Insulin Resistance Intervention After Stroke Trial
Glasgow, Scotland : U. Glasgow / Western Infirmary Updated
Paired Vagus Nerve Stimulation (VNS) With Rehabilitation for Upper Limb Function Improvement After Stroke
Guildford : Royal Surrey County Hospital
Insulin Resistance Intervention After Stroke Trial
Halifax : Calderdale Royal Hospital
Insulin Resistance Intervention After Stroke Trial
Liverpool : GB011
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Liverpool : University Hospital Aintree
Insulin Resistance Intervention After Stroke Trial
Liverpool : The Royal Liverpool and Broadgreen University Hospitals
Insulin Resistance Intervention After Stroke Trial
London : GB006
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
London : GB003
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
London : Kings College London
Insulin Resistance Intervention After Stroke Trial
London : Saint Georges University of London
Insulin Resistance Intervention After Stroke Trial
Luton : Luton and Dubstable Hospital
Insulin Resistance Intervention After Stroke Trial
Many Locations :
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
Margate : Queen Elizabeth The Queen Mother Hospital
Insulin Resistance Intervention After Stroke Trial
Middlesbrough : James Cook University Hospital
Insulin Resistance Intervention After Stroke Trial
Newcastle upon Tyne : GB001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Newcastle upon Tyne : Newcastle upon Tyne
Insulin Resistance Intervention After Stroke Trial
Oxford : Acute Vascular Imaging Centre, John Radcliffe Hospital, University of Oxford
A Study of Survival and Outcome After Stroke
Stoke on Trent : GB005
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Tooting, London : St George's Hospital
SISTERS: Spasticity In Stroke Study - Randomized Study
Torquay : Torbay Hospital (South Devon Healthcare NHS Foundation Trust)
Insulin Resistance Intervention After Stroke Trial
Tyne and Wear : North Tyneside General Hospital
Insulin Resistance Intervention After Stroke Trial
Westcliff-on-Sea : GB015
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Wolverhampton : GB013
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Venezuela
Vietnam
Hanoi : VN002
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Ho Chi Minh City : VN001
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
